Cancer – Breast – Page 2 – OncWonk – Dr Bier's Oncology Research Reviews

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows

November 2, 2025

Comment: Metronomic chemotherapy (mCHT) is a concept that’s been around, but it’s often overlooked in favor of high-dose regimens. This 2022 review from J. Clin. Med. brilliantly frames the evidence, separating the clear “lights”—like its low-toxicity profile—from the persistent “shadows” we still face, such as the lack of large randomized trials. For our frail or […]

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key

November 2, 2025

| No Comments

| Cancer - Breast TNBC, Metronomic Chemo, Uncategorized

Comment: This paper tries to identify the true clinical niche for Metronomic Chemotherapy: adjuvant maintenance therapy for patients with residual disease. This is the high-risk subgroup where the gold standard, maximum tolerated dose (MTD) chemotherapy, has clearly failed to eradicate the disease. The success of the CREATE-X trial in this specific, defined population—with its remarkable […]

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

October 26, 2025

| No Comments

| Cancer - Breast, Metronomic Chemo

Comment: The MECCA trial, while certainly not practice-changing, provides an important signal for the potential of metronomic chemotherapy. The key takeaway is the therapeutic window. Achieving a 9-month PFS benefit and a positive OS trend with a regimen that produced Grade 3 adverse events in only 15.1% of patients is compelling. This highlights the central […]

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

October 26, 2025

| No Comments

| Cancer - Breast, Cancer - Breast TNBC, Metronomic Chemo

Comment: This study presents a very practical and appealing option for managing advanced HER2-negative breast cancer in the palliative setting. The key takeaway is the dual advantage of this all-oral metronomic regimen: it demonstrates clinically relevant activity while maintaining an exceptionally low toxicity profile. However, the regimen’s main strength is its safety and convenience. Being […]

Respiratory viral infections awaken metastatic breast cancer cells in lungs

October 26, 2025

| No Comments

| Cancer - Breast, Cancers

Comment: This is an interesting and potentially alarming one. I’m sure we’ve all noted times where a stable patient started progressing after getting an infection. This study shows an association of SARS-CoV-2 infection with a nearly two-fold increase in cancer-specific mortality (UK Biobank) and a 44% higher rate of lung metastases in breast cancer patients […]

Association between Soy Isoflavone Intake and Breast Cancer Risk for Pre- and Post-Menopausal Women

October 26, 2025

| No Comments

| Cancer - Breast, Soy

Comment: This meta-analysis is a classic example of how pooling heterogeneous and methodologically different studies can create confusion. In general I am always suspicious of meta-analyses for that reason. Although it is possible that there is a biological reason for the studies on Asian women to be different than on Western, it is also possible […]

Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study

October 26, 2025

| No Comments

| Cancer - Breast, Soy

Comment: For years, people have been inappropriately scared of soy both in terms of causing breast cancer and negatively impacting progression once they have it. There is a group of people out there who are continuing to promote that despite all evidence to the contrary. The key finding of this study is not just that […]

Positive effects of soy isoflavone food on survival of breast cancer patients in China

October 25, 2025

| No Comments

| Cancer - Breast, Soy

Comment: A common question from breast cancer survivors is whether soy is safe to eat. This post breaks down a 2012 Chinese study that explored this topic. The researchers found a positive association between high soy intake and improved survival for breast cancer patients, particularly those with ER-positive tumors. Summary: Clinical Bottom Line This prospective […]

Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies

October 25, 2025

| No Comments

| Cancer - Breast, Coffee & Tea, Soy

Comment: A study looking at the impact of phytonutrients, including soy and tea. The strongest evidence is for soy isoflavones. Summary: Clinical Bottom Line This systematic review of observational studies provides “Probable” evidence that higher soy isoflavone consumption is associated with a reduced risk of breast cancer recurrence, particularly for postmenopausal and ER-positive survivors. Similarly, […]

Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy

October 25, 2025

| No Comments

| Cancer - Breast, Soy

Comment: This article shows a benefit to soy intake for ER+/PR+ patients taking AI medications, but not with tamoxifen. Summary: Clinical Bottom Line This prospective cohort study found a significant association between high dietary soy isoflavone intake (defined as >42.3 mg/day) and a reduced risk of breast cancer recurrence among postmenopausal […]